智通财经网·2025-09-15 08:52Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration of Famotidine Injection, indicating a significant advancement in the company's product portfolio and potential market opportunities [1]. Company Summary - The approved drug, Famotidine Injection, is a chemical medication independently developed by the group [1]. - The approved indication for the drug is for the treatment of upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1]. Industry Summary - The approval of Famotidine Injection highlights the ongoing innovation and development within the pharmaceutical industry, particularly in the area of gastrointestinal treatments [1].